CLINICAL TRIALS PROFILE FOR SOMAVERT
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
All Clinical Trials for Somavert
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00151437 ↗ | Canadian Pegvisomant Compassionate Study In Acromegalic Patients | Completed | Pfizer | Phase 4 | 2004-11-01 | The purposes of this study are: 1) to provide SOMAVERT for compassionate use to patients with acromegaly or who have completed clinical trials and were responsive, and 2) to evaluate the safety and tolerability of SOMAVERT. |
| NCT00476879 ↗ | Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content | Completed | Aarhus University Hospital | N/A | 2006-08-01 | The purpose of this study is to examine the effects of growth hormone during fasting in healthy lean men. |
| NCT00476879 ↗ | Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content | Completed | Pfizer | N/A | 2006-08-01 | The purpose of this study is to examine the effects of growth hormone during fasting in healthy lean men. |
| NCT00476879 ↗ | Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content | Completed | University of Aarhus | N/A | 2006-08-01 | The purpose of this study is to examine the effects of growth hormone during fasting in healthy lean men. |
| NCT00552851 ↗ | Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant | Unknown status | Pfizer | Phase 4 | 2006-06-01 | The purpose of this study is to evaluate changes in left ventricular mass and cardiac function in patients with active acromegaly before and after treatment with the growth hormone receptor antagonist pegvisomant for one year. |
| NCT00552851 ↗ | Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant | Unknown status | University of Wuerzburg | Phase 4 | 2006-06-01 | The purpose of this study is to evaluate changes in left ventricular mass and cardiac function in patients with active acromegaly before and after treatment with the growth hormone receptor antagonist pegvisomant for one year. |
| NCT00652379 ↗ | Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients | Completed | Aarhus University Hospital | N/A | 2008-06-01 | The purpose of this study is to investigate if co-treatment of acromegalic patients, who beforehand are considered well-controlled on SA monotherapy, with pegvisomant and SA will improve insulin sensitivity and glucose tolerance, and if these effects of co-treatment can be obtained at a neutral cost as compared to SA mono therapy. Second to investigate body composition, substrate metabolism, symptoms, intrahepatic and intramyocellular fat. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Somavert
Condition Name
Clinical Trial Locations for Somavert
Trials by Country
Clinical Trial Progress for Somavert
Clinical Trial Phase
Clinical Trial Sponsors for Somavert
Sponsor Name
